Found this interesting article on the high price of cancer drugs and if they are worth it in terms of efficacy. The article mentioned Sloan-Kettering's new tool to help patients decide for themselves based on how the drug affects them.
Here is a link to the article about the abacus development:
Iclusig and Bosutinib are not listed but the three main drugs for CML are.
It appears to me that Gleevec is priced appropriately, Tasigna is slightly overpriced and Sprycel is underpriced at this point based on their criteria.